DRG Epidemiology's coverage of meningococcal B vaccine comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of meningococcal B vaccine for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology's meningococcal B vaccine forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of meningococcal B vaccine over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following meningococcal b vaccine patient populations:
- Vaccine eligible population
- Newly eligible for vaccine population
Note: coverage may vary by country and region.
- Meningococcal B Vaccine - Epidemiology - Mature Markets Data
- Key Findings
- Meningococcal B Vaccine Eligible Population per 100,000 People in 2018 and 2038
- Relative Sizes of the Contributing Factors to the Trend in Total Eligible Population for the Meningococcal B Vaccine Over the Next 20 Years
- Analysis of the Total Meningococcal B Vaccine Eligible Population by Newly Eligible Status
- Key Findings
- Epidemiology Data
- Meningococcal B Vaccine Eligible Population
- Reference Materials
- Literature Review
- Studies Included in the Analysis of the Meningococcal B Vaccine Eligible Population
- Studies Excluded from the Analysis of the Meningococcal B Vaccine Eligible Population
- Risk/Protective Factors
- Risk/Protective Factors for the Meningiococcal B Vaccine
- Literature Review
Author(s): Alison Isherwood, MSc, MRes, PhD; Sandeep Mahapatra, BDS, MPH
Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.
Sandeep is a dental graduate with a Master’s in Public Health with a specialization in Epidemiology and has been associated with DRG since June 2018. He works with a global team of epidemiologists in performing fully documented systematic reviews of published and grey literature on epidemiology of diseases and their risk factors. He also conducts analysis on descriptive epidemiology of major indications in mature and developing markets. Additionally, he supports the operational and strategic management of the team and wider business unit through collation of data from various sources.
Prior to joining DRG he had over 5 years of experience working with state and central government of India to plan, design and conduct large scale research and implementation projects on non-communicable diseases, tobacco cessation and childhood nutrition.